Heart Rate Variability (HRV)-Guided Transcranial Direct Current Stimulation (tDCS)

Официальное название

HRV-Guided tDCS: Integrating A Biomarker For Clinical Utility

Обзор

This technology development project will be informed and guided by initial data collection of human subject data. For this purpose, the investigators will recruit n=100 people with mild to moderate depression in a double-blinded, parallel-arm, sham-controlled data collection period administered at home and using the investigator's remotely supervised (RS) tDCS protocol. Enrolled participants will complete 10 days of 30-minute tDCS (2.0, DLPFC left anodal) using the RS-tDCS protocol. During each daily session, standard HR and impedance-based HR (i-HR), obtained from the tDCS headset, will be collected to identify a possible marker of response to tDCS in depression. Participants will be randomized 2:1 to active vs. sham tDCS.

Вмешательства

• Устройство Active Transcranial Direct Current Stimulation (tDCS)
  tDCS will be delivered using the 1x1 Mini CT tDCS device. For active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end. Participants will receive 10 sessions of tDCS over the course of this study on weekdays (M-F).
• Устройство Sham Transcranial Direct Current Stimulation (tDCS)
  Sham tDCS will be delivered using the 1x1 Mini CT tDCS device. For sham tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end. Participants will receive 10 sessions of sham tDCS over the course of this study on weekdays (M-F).

Первичные конечные точки

• Average Heart Rate (HR) Measured Using Polar H10 Chest Monitor [Срок оценки: Up to Week 4]
• Average HR Measured Using i-HR Data Logger [Срок оценки: Up to Week 4]

Вторичные конечные точки (5)

• Change in Montgomery Ӓsberg Depression Rating Scale (MADRS) Score [Срок оценки: Baseline, End of Intervention (Up to Week 4)]
• Change in State-Trait Anxiety Inventory for Adults (STAI): State Score [Срок оценки: Baseline, End of Intervention (Up to Week 4)]
• Change in State-Trait Anxiety Inventory for Adults (STAI): Trait Score [Срок оценки: Baseline, End of Intervention (Up to Week 4)]
• Change in Positive and Negative Affect Schedule (PANAS-SF): Positive Affect Score [Срок оценки: Baseline, End of Intervention (Up to Week 4)]
• Change in Positive and Negative Affect Schedule (PANAS-SF): Negative Affect Score [Срок оценки: Baseline, End of Intervention (Up to Week 4)]

Критерии участия

Критерии включения

• Mild to moderate depression (Beck Depression Inventory(BDI)-II 14-28)
• Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-V-TR) Depressive episode
• Wide Range Achievement Test (WRAT)-4th Reading Recognition subtest standard score >85

Критерии исключения

• Primary neurologic, psychiatric (e.g., multiple sclerosis, stroke, Parkinson's disease, spinal cord injury, intracranial mass, traumatic brain injury (TBI), epilepsy, mild cognitive impairment (MCI), or dementia), or major medical disorder (e.g., history of myocardial infarction, diabetes, thyroid disease, arrhythmia, atrial fibrillation) (medical history review)
• DSM-V-TR bipolar depression, psychotic disorder, or alcohol or substance use disorder (M.I.N.I.)
• Active or high suicidality risk (Columbia-Suicide Severity Rating Scale, C-SSRS), or otherwise judged as inappropriate by the study clinicians
• History of a heart transplant, presence of permanent pacemaker implant or Left Ventricular Assist Device
• Use of certain medications that can affect heart rate variability, such as beta-blockers, calcium channel blockers, or cardiac glycosides
• Use of antidepressant, antipsychotic, anxiolytic, or stimulant medications
• Pregnant or planning pregnancy during the study period
• Seizure disorder or recent (<5 years) seizure history
• Presence of metal objects in the head/neck
• Any skin disorder or skin sensitive area near stimulation locations

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Одна группа

Маскирование

Двойное слепое

Основная цель

Другое

Центры проведения

США · 1 центр

• NYU Langone Health — New York

Идентификаторы

NCT: NCT06455527 · 24-00536

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗